Endpoints Weekly reports on iECURE's gene therapy success for OTC deficiency, FDA CDER director Patrizia Cavazzoni's departure, and Verdiva Bio's $411M launch with Sciwind assets.
Following a string of FDA resignations, Patrizia Cavazzoni has announced that her last day will be 18 January.
Patrizia Cavazzoni, leader of the FDA's Center for Drug Evaluation and Research, is leaving the agency on Jan. 18.
FDA's Center for Drug Evaluation and Research director, Patrizia Cavazzoni, MD, to step down in mid-January. Other top leaders also leaving FDA.
FDA's Patrizia Cavazzoni to retire as CDER chief in 2nd senior official's departure in span of weeks
The FDA’s influential director of the Center for Drug Evaluation and Research, Patrizia Cavazzoni, M.D., will soon retire ...
The director of the FDA's main drug review office will exit on Jan. 18, according to an email sent to staff. Her departure is ...
According to CDER Director Patrizia Cavazzoni, CDER’s new Center for Real-World Evidence Innovation represents a major step ...
It’s the second time in less than a month that retailer has recalled the medication; this time due to a potential foreign ...
Healthcare organizations may be required to bolster their cybersecurity, to better prevent sensitive information from being leaked by cyberattacks like the ones that hit Ascension and UnitedHealth ...
FRIDAY, Dec. 27, 2024 (HealthDay News) -- The U.S. Food and Drug Administration (FDA) has proposed a new rule to require standardized testing of talc-containing cosmetics for asbestos, a known ...
“Based on our review of available data, and consistent with the advice of the advisory committee, we are taking this next step in the process,” said Patrizia Cavazzoni, M.D., director of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback